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every other day. His condition has remained stable while 
tapering the dosage ( 5  mg each month) over the past few 
months. He has experienced no dysphagia at any time. 
Subclinical limb neuropathy with areflexia and al- 
buminocytological dissociation occurred within 2 months of 
our patient's initial complaint of diplopia. Symptoms of 
weakness and sensory loss, however, did not occur for an- 
other 4% years. Thus, while the onset of subclinical limb 
neuropathy within 2 months after first experiencing diplopia 
is consistent with the course of Donaghy and Earl's patients, 
the prolonged delay in developing more overt sensorimotor 
symptoms is unique. Our patient is otherwise quite similar to 
those of Donaghy and Earl except for the absence of dys- 
phagia and the apparently good response to immunosuppres- 
sive therapy thus far. In these respects, he more closely re- 
sembles the sixth case of Gibberd (2}. Our patient has, 
however, been followed for only 15 months since the onset 
of overt limb symptoms, and we recognize the possibility of 
future occurrence of such manifestations. 
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The Initial Diagnosis 
of Multiple Sclerosis 
Marc R. Nuwer, MD, PhD, Lawrence W. Myers, MD, 
and George W. Ellison, M D  
We were pleased to read the study by Gebarski and col- 
leagues {2) about the great value of magnetic resonance im- 
aging (MRI) in the initial diagnosis of multiple sclerosis (MS). 
However, we have concerns about the comparison of MRI 
with evoked potential (EP) tests. The data presented show 
that the EPs had an unusually low rate of abnormality in 
these 30 patients. Most studies of EPs in MS show much 
higher rates of abnormality, often with 90% of patients man- 
ifesting abnormalities in at least one EP modality even in the 
early stages of MS (I}. Another recent study by Tramo and 
colleagues [3} directly compared MRI and EPs in the diag- 
nosis of MS at the initial presentation of the patient, and that 
study concluded that EPs are more sensitive than MRI. Per- 
haps the study by Gebarski and colleagues shows less sen- 
sitivity of EPs because of technical differences in the way that 
the EPs were carried out. No details of the EP procedures 
were given in the Subjects and Methods section. Details of 
EP testing would be very helpful, including the visual 
stimulus equipment, check size, contrast, field size, reversal 
rate, brainstem stimulus intensity and phase, somatosensory 
stimulus site, rate and intensity, and recording sites, as well as 
the various filter settings and normal limits used. It is also 
notable that only half of the patients had somatosensory EPs 
recorded, and presumably most of these did not have lower 
extremity stimulation done (which may be the EP most often 
positive in MS). 
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We thank Drs Nuwer, Myers, and Ellison for their com- 
ments. We accepted for inclusion in our study all patients 
suspected of having multiple sclerosis following an initial 
evaluation by a neurologist on our faculty. The neurologists 
referring the patients to us ordered the ancillary laboratory 
tests, including the evoked potential studies. Many of the 
patients were referred to our neurologists from other med- 
ical centers where some laboratory tests, including evoked 
potential studies, were performed. Because of the costs in- 
volved, these were not consistently repeated in our institu- 
tion. As Drs Nuwer, Myers, and Ellison correctly point out, 
not all patients received somatosensory evoked potential 
studies. Thus, the evoked potential studies in our report had 
a lower incidence of positive results than might be expected 
based on other findings reported in the literature. The study 
by Tramo and colleagues cited by Drs Nuwer, Myers, and 
Ellison included patients who had been ill for up to two 
years. These patients could not be considered, as a group, to 
reflect the findings in patients with the initial diagnosis of 
multiple sclerosis. 
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